Induction of donor-specific tolerance or sensitization as measured by sequential MLC reactivity up to 24 months after renal transplantation.
Kahn
D
D
Department of Surgery, Medical School, Observatory, Cape Town, South Africa.
du Toit
E
E
Jacobson
J E
JE
Creemers
P
P
D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D007959:Lymphocyte Culture Test, Mixed; D008775:Methylprednisolone / Q000627:therapeutic use; D015166:Monitoring, Immunologic; D016853:Muromonab-CD3 / Q000627:therapeutic use; D013154:Spleen / Q000276:immunology; D013997:Time Factors
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D001379:Azathioprine; D008775:Methylprednisolone